J&J Appeals $1.2 Billion Arkansas Risperdal Ruling
By Jef Feeley -
Johnson & Johnson (JNJ) appealed an Arkansas judge’s decision to fine the drugmaker $1.2 billion over what state officials said was a misleading marketing campaign for the company’s antipsychotic drug Risperdal.
When J&J’s letter went out, instead of heightening doctors’ awareness of the risk of diabetes it said the opposite: “Risperdal is not associated with an increased risk of diabetes”: See our last post. Out of 1,935 distinct Adverse REactions Diabetes was the 2nd most often reported to FDA's Medwatch, but J&J didn't mislead the Doctors.
Out of 1,935 different Adverse Reactions to Risperdal, Diabetes was the #2 most often AE Reported to FDA's Medwatch. And J&J finds the State of Arkansas fines excessive.